ID | Sample | Targeted drug | Non-target therapy | Response | PFS * | Rank ** | BES *** | T | N | Distant metastases | RAS **** |
---|---|---|---|---|---|---|---|---|---|---|---|
CC-1 | Primary colorectal cancer | regorafenib | progressive disease | 3 | 160 | -62.1 | NA | NA | NA | Mut | |
CC-2 | Primary colorectal cancer | bevacizumab | FOLFOX | progressive disease | 3 | 104 | -0.9 | 3 | 2 | Yes | Mut |
CC-4 | Primary colorectal cancer | panitumumab | FOLFIRI | progressive disease | 2 | 139 | -9.5 | 4 | 2 | No | WT |
CC-5 | Primary colorectal cancer | bevacizumab | FOLFIRI | progressive disease | 5 | 81 | -0.8 | NA | 2 | Yes | Mut |
CC-6 | Primary colorectal cancer | cetuximab | FOLFIRI | progressive disease | 3 | 90 | -2.6 | 4 | 2 | Yes | WT |
CC-18 | Primary colorectal cancer | cetuximab | XELOX | progressive disease | 8 | 137 | -9.3 | 3 | 1 | Yes | WT |
CC-34 | Primary colorectal cancer | bevacizumab | FOLFOX | progressive disease | 4 | 19 | 4.4 | 4 | 2 | Yes | Mut |
CC-35 | Liver metastasis | bevacizumab | FOLFIRI | partial response | 12 | 54 | 0.1 | 3 | 1 | Yes | WT |
CC-41 | Liver metastasis | bevacizumab | FOLFOX | stable disease | 9 | 5 | 7.9 | 4 | 0 | No | WT |
CC-44 | Primary colorectal cancer | bevacizumab | FOLFOX | stable disease | 11 | 2 | 23.5 | 3 | 0 | Yes | WT |
CC-45 | Peritoneal metastasis | bevacizumab | FOLFIRINOX | stable disease | 20 | 13 | 5.1 | 4 | 1 | Yes | Mut |
CC-64 | Brain metastasis | bevacizumab | FOLFIRI | progressive disease | 5 | 6 | 24.3 | 3 | 0 | Yes | WT |
CC-65 | Primary colorectal cancer | bevacizumab | FOLFIRINOX | partial response | 6 | 22 | 3.1 | 4 | 2 | Yes | Mut |
CC-72 | Liver metastasis | aflibercept | FOLFIRI | progressive disease | 3 | 166 | -107.9 | 3 | 2 | Yes | Mut |
CC_91 | Small Intestine metastasis | bevacizumab | capecitabine | stable disease | 13 | 6 | 9.0 | 3 | 1 | Yes | Mut |
CC-94 | Adrenal Gland metastasis | bevacizumab | FOLFIRI | partial response | 5 | 27 | 6.6 | 3 | 1 | Yes | WT |
CC-95 | Liver metastasis | bevacizumab | FOLFOX | progressive disease | 4 | 99 | 0.3 | 3 | 1 | Yes | WT |
CC-105 | Primary colorectal cancer | regorafenib | progressive disease | 3 | 113 | -3.0 | 3 | 1 | Yes | WT | |
CC-107 | Primary colorectal cancer | bevacizumab | FOLFOX | stable disease | 4 | 22 | 1.7 | 3 | 2 | Yes | Mut |
CC-109 | Peritoneal metastasis | bevacizumab | FOLFIRI | stable disease | 8 | 1 | 15.7 | 4 | 0 | Yes | WT |
CC-111 | Peritoneal metastasis | bevacizumab | FOLFOX | progressive disease | 2 | 165 | -18.3 | 3 | 0 | Yes | Mut |